145
Participants
Start Date
March 17, 2016
Primary Completion Date
May 31, 2017
Study Completion Date
May 31, 2017
Mepolizumab 100mg SC
At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
Albuterol/salbutamol MDIs
Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
Omalizumab
Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
GSK Investigational Site, Florida
GSK Investigational Site, San Juan Bautista
GSK Investigational Site, La Plata
GSK Investigational Site, Rosario
GSK Investigational Site, Erpent
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Marseille
GSK Investigational Site, Rochester
GSK Investigational Site, Santiago de Compostela. La Coruña.
GSK Investigational Site, Baltimore
GSK Investigational Site, Williamsburg
GSK Investigational Site, Richmond
GSK Investigational Site, Durham
GSK Investigational Site, Pozuelo de Alarcón/Madrid
GSK Investigational Site, Charlotte
GSK Investigational Site, Murcia
GSK Investigational Site, Hanover
GSK Investigational Site, Toulouse
GSK Investigational Site, Bordeaux
GSK Investigational Site, Montpellier
GSK Investigational Site, Birmingham
GSK Investigational Site, Grenoble
GSK Investigational Site, Laredo
GSK Investigational Site, Nantes
GSK Investigational Site, Valencia
GSK Investigational Site, Neu-Isenburg
GSK Investigational Site, Lyon
GSK Investigational Site, Paris
GSK Investigational Site, Upland
GSK Investigational Site, San Diego
GSK Investigational Site, Riverside
GSK Investigational Site, Roseville
GSK Investigational Site, Piscataway
GSK Investigational Site, East Providence
GSK Investigational Site, Quilmes
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Calgary
GSK Investigational Site, Sherwood Park
GSK Investigational Site, Vancouver
GSK Investigational Site, Ajax
GSK Investigational Site, Mississauga
GSK Investigational Site, Toronto
GSK Investigational Site, Toronto
GSK Investigational Site, Windsor
GSK Investigational Site, Montreal
GSK Investigational Site, Leipzig
GSK Investigational Site, Dordrecht
GSK Investigational Site, Rotterdam
GSK Investigational Site, Barcelona
GSK Investigational Site, L'Hospitalet de Llobregat
GSK Investigational Site, Gothenburg
GSK Investigational Site, Stockholm
Lead Sponsor
GlaxoSmithKline
INDUSTRY